Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 59 entries
View as:

Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas

Phase: N/A Priority: Normal
NCT ID: NCT01504256 Org: User:
Start: 10/31/11 End: 07/31/17 Due: 07/31/18

Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers

Phase: N/A Priority: Normal
NCT ID: NCT01200121 Org: User:
Start: 02/28/10 End: 12/31/14 Due: 12/31/15

Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)

Phase: N/A Priority: Normal
NCT ID: NCT05383001 Org: User:
Start: 05/20/22 End: 05/31/26 Due: 05/31/27

Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB

Phase: N/A Priority: Normal
NCT ID: NCT02326285 Org: User:
Start: 11/30/15 End: 01/31/18 Due: 01/31/19

Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study

Phase: N/A Priority: Normal
NCT ID: NCT05089916 Org: User:
Start: 01/20/22 End: 12/31/26 Due: 12/31/27

Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients

Phase: N/A Priority: Normal
NCT ID: NCT03473574 Org: User:
Start: 05/02/18 End: 03/15/22 Due: 03/15/23

Quality Assurance of Secondary Immunodeficiencies (SID) in CLL/MM Patients

Phase: N/A Priority: Normal
NCT ID: NCT04172467 Org: User:
Start: 01/28/20 End: 08/03/20 Due: 08/03/21

Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01520103 Org: User:
Start: 01/31/12 End: 10/31/16 Due: 10/31/17

Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide

Phase: N/A Priority: Normal
NCT ID: NCT04221529 Org: User:
Start: 01/06/20 End: 04/30/25 Due: 04/30/26

Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02047513 Org: User:
Start: 07/31/15 End: 10/31/22 Due: 10/31/23

Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies

Phase: N/A Priority: Normal
NCT ID: NCT03043547 Org: User:
Start: 10/24/17 End: 03/08/22 Due: 03/08/23

Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03013946 Org: User:
Start: 01/18/17 End: 01/16/24 Due: 01/16/25

Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03409848 Org: User:
Start: 03/01/18 End: 03/05/22 Due: 03/05/23

Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT03317457 Org: User:
Start: 12/15/17 End: 08/12/22 Due: 08/12/23

Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00889343 Org: User:
Start: 03/31/09 End: 12/31/12 Due: 12/31/13

Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03044587 Org: User:
Start: 01/24/18 End: 01/31/25 Due: 01/31/26

Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01668498 Org: User:
Start: 05/31/11 End: 03/31/16 Due: 03/31/17

mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03043729 Org: User:
Start: 03/06/17 End: 06/01/22 Due: 06/01/23

Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02125136 Org: User:
Start: 11/30/14 End: 02/19/20 Due: 02/19/21

Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04727541 Org: User:
Start: 07/08/21 End: 01/05/22 Due: 01/05/23

Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT02812992 Org: User:
Start: 06/30/16 End: 02/28/21 Due: 02/28/22

Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03305913 Org: User:
Start: 07/31/17 End: 04/26/19 Due: 04/26/20

Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01627379 Org: User:
Start: 05/31/12 End: 05/31/17 Due: 05/31/18

Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach

Phase: N/A Priority: Normal
NCT ID: NCT01472029 Org: User:
Start: 12/31/11 End: 09/12/16 Due: 09/12/17

Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05190263 Org: User:
Start: 10/25/21 End: 02/06/22 Due: 02/06/23